Omeros
Manufacturing · Washington, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
201 Elliott Ave W, Seattle, Washington, ...Phone Number
(206) 676-5000Website
www.omeros.comRevenue
$9.9 MillionStock Symbol
OMERIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
3
1
1
1
1
1
About Omeros
Omeros is a Seattle-based biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded in 1994.Explore more
Omeros Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Omeros your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Check out if Omeros is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Omeros
Product Launch: Get notified when Omeros launches new products
Earning: See what the market has to say on Omeros recently announced quarterly report
Omeros, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Omeros has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Omeros has new funding data
Click to see if Omeros had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at Omeros
Find 3 more new buyers
Compare Similar Companies to Omeros
Compare insights from companies similar to Omeros, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Omeros is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Omeros is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Omeros.
Omeros financials insights
Gather financial insights about Omeros, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Stock Offering
$84M
2016
Multiple Rounds
$215M
2017
Stock Offering
$63.6M
2018
Debt
$210M
2019
Stock Offering
$57.5M
2024
Debt
$92.1M
2025
Other Financing Round
$4M
Omeros Tech Stack
A closer look at the technologies used by Omeros
See more technologies
Most Recent Scoops
Project
Omeros has confirmed that its Marketing Authorization Application (MAA) for YARTEMLEA is under review by the EMA, with orphan designation granted and centralized review eligibility confirmed, and that patent protection for the MASP-2 franchise is expected to extend to at least 2042.
Intellectual Property, Legal Affairs, Pharmaceuticals
Project
Omeros has reported pivotal trial results for YARTEMLEA in TA-TMA, demonstrating a 61% complete response rate and 73% 100-day overall survival from diagnosis, with an external control analysis showing a three- to fourfold lower mortality risk compared to controls.
Medical Research
Project
Omeros has announced that candidate selection is underway for its oral once-daily small molecule MASP-2 inhibitor program, with IND-enabling studies as the next step and potential indications spanning renal and neurodegenerative disorders involving endothelial injury and thromboinflammation.
Medical Research, Pharmaceuticals
Project
Omeros has announced that a J-code for YARTEMLEA will be effective July 1 and that New Technology Add-on Payment (NTAP) is expected October 1, advancing the reimbursement infrastructure to support the ongoing commercial launch.
Product Launch
Project
Medical Research, Pharmaceuticals, Clinical Operations
Omeros News & Media
Omeros Corporation Q4 2025 Earnings Call Summary
Moby summary of Omeros Corporation's Q4 2025 earnings callOmeros Corp (OMER) Q4 2025 Earnings Call Highlights: A Turnaround with Strategic Deals and FDA ...
Omeros Corp (OMER) reports a significant net income turnaround, bolstered by a major transaction with Novo Nordisk and the FDA approval of YARTEMLEA.Omeros Q4 Earnings Call Highlights
Omeros (NASDAQ:OMER) executives highlighted two “major successes” in the fourth quarter of 2025 that they said marked a turning point for the company: closing a $240 million upfront asset sale and license deal with Novo Nordisk for the phase III-ready complement asset zaltenibart, and receiving FDAWhy Omeros Stock Skyrocketed Today
The company is on the brink of commercializing a unique medication.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Omeros
Sign Up For FreeTo access detailed company insights
Omeros is a Seattle-based biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded in 1994.... Read More
